Indirect and Direct Mapping of the Cancer-Specific EORTC QLQ-C30 onto EQ-5D-5L Utility Scores

被引:7
作者
Meunier, Aurelie [1 ]
Soare, Alexandra [1 ]
Chevrou-Severac, Helene [2 ]
Myren, Karl-Johan [2 ]
Murata, Tatsunori [3 ]
Longworth, Louise [1 ]
机构
[1] PHMR Ltd, London NW1 8XY, England
[2] Alex Pharma GmbH, Zurich, Switzerland
[3] CRECON Res & Consulting Inc, Tokyo, Japan
关键词
QUALITY-OF-LIFE; COMPLEMENT INHIBITOR ECULIZUMAB; MIXTURE REGRESSION-MODELS; EUROPEAN-ORGANIZATION; QUESTIONNAIRE; VALUES;
D O I
10.1007/s40258-021-00682-0
中图分类号
F [经济];
学科分类号
02 ;
摘要
Objective The aim of this study was to develop a response mapping algorithm to predict EQ-5D-5L utilities from European Organisation for Research and Treatment Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) scores and compare performance with direct mapping approaches to identify the best performing algorithm. Methods The Multi-Instrument Comparison dataset contains responses to both the EQ-5D-5L and QLQ-C30 questionnaires from 692 individuals with a broad range of cancers. Response mapping was conducted, fitting ordered logistic regressions to predict response levels for each of the five EQ-5D dimensions and utilities were predicted using the US and Japanese EQ-5D-5L value sets to test the algorithm performance. Various direct mapping models were fitted: ordinary least squares, tobit, two-part (TPM), adjusted limited dependent variable mixture and beta mixture models. Model assessment and recommendations regarding the best mapping algorithm was based on goodness-of-fit statistics, predictive ability (measures of error, distribution of predicted utilities) and in sample cross-validation. Results The response mapping model performed well in terms of predictive ability and measurement error using the US or Japanese value set, with mean absolute error ranging from 0.0708 to 0.0988, and comparably to the TPM, which was the best performing direct algorithm. Conclusion The developed mapping algorithms enable the prediction of EQ-5D-5L utilities from QLQ-C30 scores when EQ-5D-5L data have not been directly collected in clinical trials. The response mapping model offers the possibility of predicting EQ-5D-5L utility values using any national value set and can be generalised to multiple countries and oncology settings.
引用
收藏
页码:119 / 131
页数:13
相关论文
共 45 条
  • [11] EQ-5D and the EuroQol Group: Past, Present and Future
    Devlin, Nancy J.
    Brooks, Richard
    [J]. APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2017, 15 (02) : 127 - 137
  • [12] A command for fitting mixture regression models for bounded dependent variables using the beta distribution
    Gray, Laura A.
    Alava, Monica Hernandez
    [J]. STATA JOURNAL, 2018, 18 (01) : 51 - 75
  • [13] Development of a disease-specific quality of life questionnaire for patients with aplastic anemia and/or paroxysmal nocturnal hemoglobinuria (QLQ-AA/PNH)-report on phases I and II
    Groth, Martha
    Singer, Susanne
    Niedeggen, Cathrin
    Petermann-Meyer, Andrea
    Roeth, Alexander
    Schrezenmeier, Hubert
    Hoechsmann, Britta
    Bruemmendorf, Tim H.
    Panse, Jens
    [J]. ANNALS OF HEMATOLOGY, 2017, 96 (02) : 171 - 181
  • [14] MEASURING HEALTH-RELATED QUALITY-OF-LIFE
    GUYATT, GH
    FEENY, DH
    PATRICK, DL
    [J]. ANNALS OF INTERNAL MEDICINE, 1993, 118 (08) : 622 - 629
  • [15] Mapping EORTC QLQ-C30 and FACT-G onto EQ-5D-5L index for patients with cancer
    Hagiwara, Yasuhiro
    Shiroiwa, Takeru
    Taira, Naruto
    Kawahara, Takuya
    Konomura, Keiko
    Noto, Shinichi
    Fukuda, Takashi
    Shimozuma, Kojiro
    [J]. HEALTH AND QUALITY OF LIFE OUTCOMES, 2020, 18 (01)
  • [16] The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria
    Hillmen, Peter
    Young, Neal S.
    Schubert, Joerg
    Brodsky, Robert A.
    Socie, Gerard
    Muus, Petra
    Roeth, Alexander
    Szer, Jeffrey
    Elebute, Modupe O.
    Nakamura, Ryotaro
    Browne, Paul
    Risitano, Antonio M.
    Hill, Anita
    Schrezenmeier, Hubert
    Fu, Chieh-Lin
    Maciejewski, Jaroslaw
    Rollins, Scott A.
    Mojcik, Christopher F.
    Rother, Russell P.
    Luzzatto, Lucio
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (12) : 1233 - 1243
  • [17] ICER IfCaER, ICERS REF CAS EC EV, P2021
  • [18] Ikeda S., 2015, Journal of the National Institute of Public Health, V64, P47
  • [19] Derivation of Utility Values from European Organization for Research and Treatment of Cancer Quality of Life-Core 30 Questionnaire Values in Lung Cancer
    Jang, Raymond W.
    Isogai, Pierre K.
    Mittmann, Nicole
    Bradbury, Penelope A.
    Shepherd, Frances A.
    Feld, Ronald
    Leighl, Natasha B.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : 1953 - 1957
  • [20] QLU-C10D: a health state classification system for a multi-attribute utility measure based on the EORTC QLQ-C30
    King, M. T.
    Costa, D. S. J.
    Aaronson, N. K.
    Brazier, J. E.
    Cella, D. F.
    Fayers, P. M.
    Grimison, P.
    Janda, M.
    Kemmler, G.
    Norman, R.
    Pickard, A. S.
    Rowen, D.
    Velikova, G.
    Young, T. A.
    Viney, R.
    [J]. QUALITY OF LIFE RESEARCH, 2016, 25 (03) : 625 - 636